✦ LIBER ✦

PCN108 SOCIETAL COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED TREATMENT IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN ITALY

✍ Scribed by E Mueller; M Nuijten; S Ravera; S Stanisic; S Walzer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Societal cost savings through bevacizuma

✍ Stanisic, Sanja; Bischoff, Helge G.; Heigener, David F.; Vergnenègre, Alain; de 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 197 KB

PCN105 COST SAVINGS ASSOCIATED WITH BEVA

✍ E Schmidt; HG Bischoff; DF Heigener; S Stanisic; S Walzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN107 FIRST-LINE TREATMENT OF METASTATI

✍ S Stanisic; Carpeño JD Castro; S Walzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN104 SOCIETAL COST SAVINGS IN METASTAT

✍ S Stanisic; A Vergnenegre; C Chouaid; E Mueller; S Walzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CA

✍ A Gabriel; O Pirk; W Kotowa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN7 THE LIFETIME COST OF GEFITINIB (“IR

✍ A Haiderali; W Chin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB